Nycomed Amersham sells unit

Article Abstract:

Nycomed Amersham PLC announced that it is selling off 70% of its Nycomed Pharma pharmaceuticals subsidiary to Nordic Capital. Nycomed Amersham is selling the subsidiary for 340 million pound sterling ($553.7 million). Nycomed Pharma will be controlled and run by Nordic Capital, a private equity firm based in Oslo, Norway. The remaining 30% share will be held by Nycomed Amersham after it invests 21 million pound sterling into the firm.

Comment:

Nycomed Amersham to sell 70% of Nycomed Pharma to Nordic Capital for 340 mil pound sterling ($553.7 mil)

Asset sales & divestitures, Acquisitions & mergers, Foreign operations, Norway, Inorganic Chemicals, Other Basic Inorganic Chemical Manufacturing, Mergers, acquisitions and divestments, Chemical industry, Inorganic compounds, Nordic Capital, Nycomed Pharma

---

Nycomed Amersham posts 12% rise in pretax profit

Article Abstract:

Nycomed Amersham PLC announced that its pretax profits for 1998 increased 12% to 222.8 million pound sterling ($358 million). In 1997, the company posted 198.6 million pound sterling in pretax profits. The 1998 figures were higher than what analysts had predicted. Nycomed also posted a total of 32 million pound sterling in cost savings from the merger of Amersham, Nycomed, and Pharmacia Biotech.

Comment:

Pretax profits for 1998 increase 12% to 222.8 million pound sterling ($358 million)

Sales, profits & dividends, Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Biotechnology industry, Biotechnology industries, Finance, Abstract

---

Nycomed Amersham wins key ruling on genetic code

Article Abstract:

The article discusses the key ruling Nycomed Amersham PLC has won at the expense of Applera Corp.'s Applied Biosytems Group. At stake is a patent for colored dyes used to label the four letters--A, T, C and G--that spell out the DNA sequence.

Biological Product (except Diagnostic) Manufacturing, Drugs, Biological Products, Patents & copyrights, Pharmaceutical industry, Biological products industry, Intellectual property, GE Healthcare, Applied Biosystems Ltd.

Similar abstracts:

• Abstracts: Societe Generale's net profit sinks. Societe Generale posts strong profit
• Abstracts: DaimlerChrysler assumes control of 3 Smart dealers. Singapore Airlines posts 33% increase in annual net profit
• Abstracts: ThyssenKrupp projects 1.3 billion euros in pretax profit. Usinor expects steel-price pressures
• Abstracts: Grupo Televisa owners shore up control with debt restructuring. Deal between EM.TV and Kirch is in danger
• Abstracts: AOL explores a possible sale of DVD and CD manufacturer. EMI's Levy may reprise role is music kingmaker

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.